Talk:Velpatasvir

This is the talk page for discussing improvements to the Velpatasvir article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Velpatasvir.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

ATC code missing

The ATC code seems to be missing. — Preceding unsigned comment added by Tommycarstensen (talk • contribs) 07:17, 7 August 2020 (UTC)[reply]

Mechanism of action seems erroneous

"Velpatasvir is an NS5A inhibitor" indicates that the drug is an inhibitor of the RNA-dependent RNA-polymerase (RdRP) of the virus, which is further detailed under "Mechanism of action", where it says:"The substance blocks NS5A, a protein necessary for hepatitis C virus replication and assembly."

But under "Interactions" it says:"Velpatasvir is both an inhibitor and a substrate of the transporter proteins P-glycoprotein (Pgp), ABCG2, OATP1B1 and OATP1B3". The latter means that Velpatasvir is an inhibitor of multidrug-resistance-transporters (MDR transporters). So I assume, since Velpatasvir is given in combination with Sofosbuvir, which is, itself, an NS5A-inhibitor (i.e. an RdRP-inhibitor), Velpatasvir is actually not an RdRP-inhibitor but given in combination with Sofosbuvir to prevent cells from exporting the actual RdRP-inhibitor (Sofosbuvir).

Furthermore, it is difficult to imagine a drug that is both a specific inhibitor of an RdRP and MDRs. Plus, the chemical structure of Velpatasvir looks nothing like the ones of RNA-polymerase inhibitors (which are nucletide analogues).

Could the author please look into the issue? --Felix Tritschler (talk) 19:17, 23 March 2020 (UTC)[reply]

Hi Felix! The virus's RNA-dependent RNA-polymerase is NS5B (not NS5A) and is inhibited by sofosbuvir. Velpatasvir inhibits NS5A, whose precise function seems to be somewhat unclear. (Our article says it might be a transcriptional activator.) I agree that, being a P-gp inhibitor, velpatasvir might also increase sofosbuvir levels, but at the moment I can't find a source supporting this. At any rate, velpatasvir does not seem to be a specific inhibitor of P-gp and OATPs, it just happens to block them like dozens or hundreds of other pharmaceuticals do. Best regards, ἀνυπόδητος (talk) 09:08, 24 March 2020 (UTC)[reply]

Incorrect structure

The structure in the article is incorrect - the ethoxy group in the lower-left part is supposed to be methoxymethyl - i.e. the oxygen should be moved one atom. 147.231.120.62 (talk) 05:54, 4 March 2024 (UTC)[reply]